Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Highly Bioavailable Curcumin on Subjective Tinnitus
NCT04800107Withdrawn
- Sponsor
- Henry Ford Health
- Start
- Jan 2021
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Randomised, double-blind trial of phosphatidylcholine-curcumin complex in tinnitus (2 arms), sponsored by Henry Ford Health. Primary endpoint: Tinnitus Functional Index at 30 days. Planned start Jan 2021; status: withdrawn.
02
Drugs
phosphatidylcholine-curcumin complex
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT04800107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04800107.